Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 983 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer of Esophagus Clear all
Terminated No phase listed Observational

WavSTAT® Optical Biopsy System to Target Esophageal Biopsies

NCT00747136
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
SpectraScience
Other
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 9, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional Results available

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

NCT02062632
View directory record Official record
Conditions
Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions
Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

NCT01298999
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
YF476, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 9, 2026, 2:58 PM EDT
Suspended Phase 4 Interventional

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

NCT02366819
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Stage IIB Gastric Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Gastric Cancer
Interventions
Oxaliplatin, Leucovorin Calcium, Irinotecan Hydrochloride, Fluorouracil, Conventional Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Active, not recruiting Phase 1 Interventional

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

NCT05539430
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Interventions
LB1908
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Tampa, Florida • Detroit, Michigan • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus

NCT01288612
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Sedated Endoscopy, Transnasal Endoscopy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 95 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Oct 9, 2026, 2:58 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus

NCT00208936
View directory record Official record
Conditions
Esophageal Diseases
Interventions
Taxol, Cisplatin, 5-Fluorouracil, G-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 9, 2026, 2:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

NCT02584244
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Interventions
LUM015, LUM 2.6 Imaging Device
Drug · Device
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Recruiting Phase 1 Interventional

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601
View directory record Official record
Conditions
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
Interventions
LY4257496, Standard of Care Anticancer Therapies, LY4257529
Drug · Diagnostic Test
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
16
States / cities
Duarte, California • Santa Monica, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

NCT03490292
View directory record Official record
Conditions
Resectable Esophageal Cancer, GastroEsophageal Cancer
Interventions
Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel, Radiation
Combination Product · Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Doxil Topotecan Doublet Cancer Study

NCT00252889
View directory record Official record
Conditions
Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
Interventions
Topotecan and pegylated doxorubicin
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

NCT00165490
View directory record Official record
Conditions
Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
Interventions
Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery
Drug · Device · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 9, 2026, 2:58 PM EDT
Recruiting Phase 1 Interventional

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

NCT07227168
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
Interventions
STRO-004, Pembrolizumab
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Recruiting Phase 2 Interventional

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

NCT05563766
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Itraconazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Terminated Not applicable Interventional Results available

TECR & ECM Placement for Esophageal High Grade Dysplasia

NCT02396745
View directory record Official record
Conditions
Barrett Esophagus, Esophagus, High Grade Dysplasia
Interventions
Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 9, 2026, 2:58 PM EDT
Active, not recruiting No phase listed Observational

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

NCT06335966
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Screening with swallowable esophageal cell-collection devices (SECD)
Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of D-Methadone in Patients With Chronic Pain

NCT00588640
View directory record Official record
Conditions
Pain, Bladder Cancer, Breast Cancer, CNS Cancer, Colon Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer, Head and Neck Cancer, Eye Cancer, Otorhinolaryngologic Neoplasms
Interventions
D-methadone, placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 9, 2026, 2:58 PM EDT
Not listed Not applicable Interventional

Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System

NCT02864043
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
NvisionVLE with Real Time Targeting, esophagogastroduodenoscopy (EGD)
Device · Procedure
Lead sponsor
NinePoint Medical
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Irvine, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 9, 2026, 2:58 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

NCT04248452
View directory record Official record
Conditions
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
453
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 2:58 PM EDT
Completed No phase listed Observational

The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy

NCT03859557
View directory record Official record
Conditions
GERD, Barrett Esophagus, Low Grade Esophageal Glandular Dysplasia, Esophageal Diseases
Interventions
Not listed
Lead sponsor
CDx Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 9, 2026, 2:58 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus

NCT00903136
View directory record Official record
Conditions
Esophageal Cancer, Precancerous Condition
Interventions
questionnaire administration, comparison of screening methods, diagnostic endoscopic procedure, esophagogastroduodenoscopy, tethered capsule endoscopy
Other · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 9, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

NCT00130689
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis
Interventions
Cetuximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 9, 2026, 2:58 PM EDT
Terminated Phase 1 Interventional

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT05252416
View directory record Official record
Conditions
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 9, 2026, 2:58 PM EDT